Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

by Paul Lelieveld | Jun 30, 2020 | Meneldor News

For the first time, this research explains the cascade of events linking influenza virus-induced activation of the Raf/MEK/ERK pathway to the nuclear export of viral ribonucleoprotein (vRNP) via the host protein RSK Raf/MEK/ERK/RSK pathway represents an Achilles heel...

Aptamer Group on BBC Look North 17th June 2020

by Paul Lelieveld | Jun 19, 2020 | Meneldor News

<iframe width=”1280″ height=”720″ src=”https://www.youtube.com/embed/5baFpqZMMac” frameborder=”0″ allow=”accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture”...

LightOx May 2020

by Paul Lelieveld | Jun 19, 2020 | Meneldor News

Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study

by Paul Lelieveld | May 28, 2020 | Meneldor News

ATR-002 mode of action inhibits SARS-CoV-2 viral propagation and prevents the cytokine storm as demonstrated in preclinical studies Atriva’s lead product candidate is the only host-targeted antiviral specifically developed to treat respiratory infections with RNA...

Therapieansätze gegen das Wuhan-Virus Deutsche Forscher entwickeln Impfstoffe gegen Coronaviren

by Paul Lelieveld | Feb 3, 2020 | Meneldor News

Jahrelang war das Interesse an der Erforschung von Coronaviren gering. Jetzt schaut die Welt, was aus den Biologie-Labors gegen die Seuche helfen könnte. Nun ist das Coronavirus, wie zu erwarten, auch in Deutschland angekommen. Spätestens jetzt dürfte auch all jenen,...